Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thromboembolic Events Clear all
Completed No phase listed Observational

VTE Prophylaxis Guidelines in Hospitalized Elders

NCT03025100
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
View directory record Official record
Conditions
Symptomatic Venous Thromboembolism (VTE)
Interventions
REGN7508, Acetylsalicylic Acid (ASA), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
30
States / cities
La Mesa, California • Rancho Mirage, California • Lone Tree, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

NCT01583218
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Betrixaban, Enoxaparin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
7,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
75
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated No phase listed Observational

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

NCT05421533
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Fullerton, California • Boca Raton, Florida • Homestead, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

NCT00531843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

NCT00182143
View directory record Official record
Conditions
Critical Illness, Deep Venous Thrombosis
Interventions
LMWH (Fragmin, dalteparin), Unfractionated Heparin
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
3,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Rochester, Minnesota • St Louis, Missouri • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2011 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Results available

Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy

NCT04352439
View directory record Official record
Conditions
Venous Thromboembolism, Ovarian Cancer
Interventions
Aspirin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Sarasota, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events

NCT04574895
View directory record Official record
Conditions
Venous Thromboembolism, Pediatrics, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Hematology Review
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years to 21 Years
Enrollment
17,427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

NCT03395639
View directory record Official record
Conditions
Cardiac Disease
Interventions
Edoxaban, Standard of Care (SOC)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

NCT02923115
View directory record Official record
Conditions
Pulmonary Embolism, Thrombotic Disease
Interventions
DS-1040b, Placebo, Enoxaparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated No phase listed Observational

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

NCT05819125
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
21,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

NCT00402467
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban, (BAY59-7939), Enoxaparine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

NCT00398216
View directory record Official record
Conditions
Thrombosis, Hip Replacement
Interventions
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Hartford, Connecticut • Sarasota, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Not applicable Interventional Results available

AMPLATZER Cardiac Plug Clinical Trial

NCT01118299
View directory record Official record
Conditions
Atrial Fibrillation, Ischemic Stroke, Peripheral Thromboembolism
Interventions
AMPLATZER Cardiac Plug
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • Littleton, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Sep 24, 2026, 4:06 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Systematic Review and Meta-Analysis of Venous Thromboembolism (VTE) Risk Assessment in Hospitalized Medical Patients

NCT01446510
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Application of VTE Risk Assessment
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Phase 3 Interventional

DOAC - Dosing Options in AntiCoagulation Prophylaxis

NCT07005024
View directory record Official record
Conditions
Cancer, VTE (Venous Thromboembolism)
Interventions
Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00020189
View directory record Official record
Conditions
Head and Neck Cancer, Thromboembolism
Interventions
acetylsalicylic acid, alvocidib, clopidogrel bisulfate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 24, 2026, 4:06 PM EDT
Completed No phase listed Observational

Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data

NCT04736420
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban, Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
78,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed No phase listed Observational

Octagam 5% Versus Comparator Post Marketing Trial

NCT01859754
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
Octagam 5%, Other marketed IVIG product
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
27
States / cities
Granada Hills, California • Irvine, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

NCT00721760
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin sodium, Semuloparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 24, 2026, 4:06 PM EDT
Withdrawn Phase 4 Interventional

Evaluation of Wound Drainage After Knee or Hip Arthroplasty

NCT02054936
View directory record Official record
Conditions
Complications; Arthroplasty
Interventions
Rivaroxaban (Xarelto), Warfarin (Coumadin)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 24, 2026, 4:06 PM EDT
Withdrawn No phase listed Observational

Evaluation of the Short and Long Term Performance and Clinical Outcomes of the Crux Vena Cava Filter System

NCT02420626
View directory record Official record
Conditions
Pulmonary Embolism, Venous Thromboembolism, Deep Vein Thrombosis
Interventions
Not listed
Lead sponsor
Volcano Corporation
Industry
Eligibility
19 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Raleigh, North Carolina • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Sep 24, 2026, 4:06 PM EDT